# Klaviyo, Inc.: financial statements, quarterly

KVYO · NYSE · CIK 1835830 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kvyo.md) · [Financials](/companies/kvyo/financials.md) · [Filings](/companies/kvyo/filings.md) · [Insiders](/companies/kvyo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kvyo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [176](/filings/0001835830-24-000109.md) | [202 d](/filings/0001835830-26-000007.md) | [210](/filings/0001835830-25-000054.md) | [222](/filings/0001835830-25-000084.md) | [235](/filings/0001835830-25-000110.md) | [270 d](/filings/0001835830-26-000007.md) | [280](/filings/0001835830-26-000027.md) | [293](/filings/0001835830-26-000040.md) | [311](/filings/0001835830-25-000110.md) | [350 d](/filings/0001835830-26-000007.md) | [358](/filings/0001835830-26-000027.md) | [371](/filings/0001835830-26-000040.md) |
| Cost of revenue | $m | [58.8](/filings/0001835830-24-000109.md) | [45.0 d](/filings/0001835830-26-000007.md) | [44.9](/filings/0001835830-25-000054.md) | [50.3](/filings/0001835830-25-000084.md) | [54.4](/filings/0001835830-25-000110.md) | [71.7 d](/filings/0001835830-26-000007.md) | [67.7](/filings/0001835830-26-000027.md) | [71.2](/filings/0001835830-26-000040.md) | [76.1](/filings/0001835830-25-000110.md) | [97.4 d](/filings/0001835830-26-000007.md) | [89.1](/filings/0001835830-26-000027.md) | [101](/filings/0001835830-26-000040.md) |
| Gross profit | $m | [117](/filings/0001835830-24-000109.md) | [157 d](/filings/0001835830-26-000007.md) | [165](/filings/0001835830-25-000054.md) | [172](/filings/0001835830-25-000084.md) | [181](/filings/0001835830-25-000110.md) | [198 d](/filings/0001835830-26-000007.md) | [212](/filings/0001835830-26-000027.md) | [222](/filings/0001835830-26-000040.md) | [235](/filings/0001835830-25-000110.md) | [253 d](/filings/0001835830-26-000007.md) | [269](/filings/0001835830-26-000027.md) | [269](/filings/0001835830-26-000040.md) |
| Research and development | $m | [141](/filings/0001835830-24-000109.md) | [52.6 d](/filings/0001835830-26-000007.md) | [56.1](/filings/0001835830-25-000054.md) | [55.7](/filings/0001835830-25-000084.md) | [55.8](/filings/0001835830-25-000110.md) | [70.9 d](/filings/0001835830-26-000007.md) | [69.3](/filings/0001835830-26-000027.md) | [72.5](/filings/0001835830-26-000040.md) | [72.7](/filings/0001835830-25-000110.md) | [76.7 d](/filings/0001835830-26-000007.md) | [80.0](/filings/0001835830-26-000027.md) | [91.9](/filings/0001835830-26-000040.md) |
| Operating income | $m | [(302)](/filings/0001835830-24-000109.md) | [(36.3) d](/filings/0001835830-26-000007.md) | [(22.1)](/filings/0001835830-25-000054.md) | [(14.1)](/filings/0001835830-25-000084.md) | [(13.3)](/filings/0001835830-25-000110.md) | [(34.7) d](/filings/0001835830-26-000007.md) | [(23.8)](/filings/0001835830-26-000027.md) | [(31.3)](/filings/0001835830-26-000040.md) | [(10.8)](/filings/0001835830-25-000110.md) | [(1.8) d](/filings/0001835830-26-000007.md) | [1.7](/filings/0001835830-26-000027.md) | [(15.0)](/filings/0001835830-26-000040.md) |
| Income tax | $m | [0.8](/filings/0001835830-24-000109.md) | [(0.6) d](/filings/0001835830-26-000007.md) | [0.4](/filings/0001835830-25-000054.md) | [0.9](/filings/0001835830-25-000084.md) | [(1.2)](/filings/0001835830-25-000110.md) | [2.4 d](/filings/0001835830-26-000007.md) | [(1.1)](/filings/0001835830-26-000027.md) | [1.8](/filings/0001835830-26-000040.md) | [(0.2)](/filings/0001835830-25-000110.md) | [0.7 d](/filings/0001835830-26-000007.md) | [1.7](/filings/0001835830-26-000027.md) | [1.7](/filings/0001835830-26-000040.md) |
| Net income | $m | [(297)](/filings/0001835830-24-000109.md) | [(26.3) d](/filings/0001835830-26-000007.md) | [(12.9)](/filings/0001835830-25-000054.md) | [(4.9)](/filings/0001835830-25-000084.md) | [(1.3)](/filings/0001835830-25-000110.md) | [(27.0) d](/filings/0001835830-26-000007.md) | [(14.1)](/filings/0001835830-26-000027.md) | [(24.3)](/filings/0001835830-26-000040.md) | [(0.4)](/filings/0001835830-25-000110.md) | [7.0 d](/filings/0001835830-26-000007.md) | [9.0](/filings/0001835830-26-000027.md) | [(8.8)](/filings/0001835830-26-000040.md) |
| Diluted EPS | $ per share | [(1.24)](/filings/0001835830-24-000109.md) | not reported | [(0.05)](/filings/0001835830-25-000054.md) | [(0.02)](/filings/0001835830-25-000084.md) | [(0.01)](/filings/0001835830-25-000110.md) | not reported | [(0.05)](/filings/0001835830-26-000027.md) | [(0.09)](/filings/0001835830-26-000040.md) | [0.00](/filings/0001835830-25-000110.md) | not reported | [0.03](/filings/0001835830-26-000027.md) | [(0.03)](/filings/0001835830-26-000040.md) |
| Basic EPS | $ per share | [(1.24)](/filings/0001835830-24-000109.md) | not reported | [(0.05)](/filings/0001835830-25-000054.md) | [(0.02)](/filings/0001835830-25-000084.md) | [(0.01)](/filings/0001835830-25-000110.md) | not reported | [(0.05)](/filings/0001835830-26-000027.md) | [(0.09)](/filings/0001835830-26-000040.md) | [0.00](/filings/0001835830-25-000110.md) | not reported | [0.03](/filings/0001835830-26-000027.md) | [(0.03)](/filings/0001835830-26-000040.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [723](/filings/0001835830-23-000008.md) | [739](/filings/0001835830-25-000014.md) | [756](/filings/0001835830-24-000055.md) | [794](/filings/0001835830-24-000079.md) | [827](/filings/0001835830-24-000109.md) | [881](/filings/0001835830-26-000007.md) | [888](/filings/0001835830-25-000054.md) | [936](/filings/0001835830-25-000084.md) | [980](/filings/0001835830-25-000110.md) | [1,065](/filings/0001835830-26-000040.md) | [985](/filings/0001835830-26-000027.md) | [833](/filings/0001835830-26-000040.md) |
| Current assets | $m | [781](/filings/0001835830-23-000008.md) | [803](/filings/0001835830-25-000014.md) | [826](/filings/0001835830-24-000055.md) | [872](/filings/0001835830-24-000079.md) | [916](/filings/0001835830-24-000109.md) | [980](/filings/0001835830-26-000007.md) | [1,007](/filings/0001835830-25-000054.md) | [1,061](/filings/0001835830-25-000084.md) | [1,110](/filings/0001835830-25-000110.md) | [1,206](/filings/0001835830-26-000040.md) | [1,146](/filings/0001835830-26-000027.md) | [1,008](/filings/0001835830-26-000040.md) |
| Total assets | $m | [1,071](/filings/0001835830-23-000008.md) | [1,089](/filings/0001835830-25-000014.md) | [1,108](/filings/0001835830-24-000055.md) | [1,150](/filings/0001835830-24-000079.md) | [1,193](/filings/0001835830-24-000109.md) | [1,273](/filings/0001835830-26-000007.md) | [1,347](/filings/0001835830-25-000054.md) | [1,398](/filings/0001835830-25-000084.md) | [1,465](/filings/0001835830-25-000110.md) | [1,581](/filings/0001835830-26-000040.md) | [1,524](/filings/0001835830-26-000027.md) | [1,384](/filings/0001835830-26-000040.md) |
| Current liabilities | $m | [120](/filings/0001835830-23-000008.md) | [131](/filings/0001835830-25-000014.md) | [130](/filings/0001835830-24-000055.md) | [132](/filings/0001835830-24-000079.md) | [142](/filings/0001835830-24-000109.md) | [200](/filings/0001835830-26-000007.md) | [193](/filings/0001835830-25-000054.md) | [214](/filings/0001835830-25-000084.md) | [227](/filings/0001835830-25-000110.md) | [282](/filings/0001835830-26-000040.md) | [271](/filings/0001835830-26-000027.md) | [322](/filings/0001835830-26-000040.md) |
| Total liabilities | $m | [166](/filings/0001835830-23-000008.md) | [174](/filings/0001835830-25-000014.md) | [171](/filings/0001835830-24-000055.md) | [170](/filings/0001835830-24-000079.md) | [178](/filings/0001835830-24-000109.md) | [239](/filings/0001835830-26-000007.md) | [283](/filings/0001835830-25-000054.md) | [301](/filings/0001835830-25-000084.md) | [323](/filings/0001835830-25-000110.md) | [384](/filings/0001835830-26-000040.md) | [370](/filings/0001835830-26-000027.md) | [417](/filings/0001835830-26-000040.md) |
| Shareholders' equity | $m | [905](/filings/0001835830-24-000109.md) | [915](/filings/0001835830-26-000007.md) | [937](/filings/0001835830-25-000084.md) | [980](/filings/0001835830-25-000110.md) | [1,015](/filings/0001835830-25-000110.md) | [1,034](/filings/0001835830-26-000040.md) | [1,064](/filings/0001835830-26-000040.md) | [1,097](/filings/0001835830-26-000040.md) | [1,142](/filings/0001835830-25-000110.md) | [1,197](/filings/0001835830-26-000040.md) | [1,153](/filings/0001835830-26-000040.md) | [967](/filings/0001835830-26-000040.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [23.7 d](/filings/0001835830-24-000109.md) | [38.6 d](/filings/0001835830-26-000007.md) | [26.2](/filings/0001835830-25-000054.md) | [40.9 d](/filings/0001835830-25-000084.md) | [38.8 d](/filings/0001835830-25-000110.md) | [60.1 d](/filings/0001835830-26-000007.md) | [14.4](/filings/0001835830-26-000027.md) | [55.7 d](/filings/0001835830-26-000040.md) | [54.8 d](/filings/0001835830-25-000110.md) | [93.2 d](/filings/0001835830-26-000007.md) | [34.3](/filings/0001835830-26-000027.md) | [93.9 d](/filings/0001835830-26-000040.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001835830-24-000109.md) | [2.8 d](/filings/0001835830-26-000007.md) | [1.3](/filings/0001835830-25-000054.md) | [0.8 d](/filings/0001835830-25-000084.md) | [1.5 d](/filings/0001835830-25-000110.md) | [2.3 d](/filings/0001835830-26-000007.md) | [2.7](/filings/0001835830-26-000027.md) | [2.1 d](/filings/0001835830-26-000040.md) | [2.3 d](/filings/0001835830-25-000110.md) | [2.5 d](/filings/0001835830-26-000007.md) | [11.7](/filings/0001835830-26-000027.md) | [6.6 d](/filings/0001835830-26-000040.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001835830-26-000027.md) | [0.0 d](/filings/0001835830-26-000040.md) | not reported | not reported | [100](/filings/0001835830-26-000027.md) | [234 d](/filings/0001835830-26-000040.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | period not labelled (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [232](/filings/0001835830-23-000008.md) | [268](/filings/0001835830-24-000055.md) | [269](/filings/0001835830-24-000079.md) | [240](/filings/0001835830-24-000109.md) | [261](/filings/0001835830-25-000054.md) | [265](/filings/0001835830-25-000084.md) | [268](/filings/0001835830-25-000110.md) | [274](/filings/0001835830-26-000027.md) | [285](/filings/0001835830-26-000040.md) | [301](/filings/0001835830-25-000110.md) | [306](/filings/0001835830-26-000027.md) | [297](/filings/0001835830-26-000040.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.